Since ICAM-1 expression is upregulated when SCLC cells acquire resistance to etoposide (Figure 5a and b, and Supplementary Figure 6), patients with HER2-positive and etoposide-resistant SCLC are ideal candidates for trastuzumab-based therapy. Here, ICAM1 is linked to small cell lung carcinoma.